Evidence map›Paper›PMID 31295151›Full record

ArticleClinical and translational gastroenterology2019

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.

Zuzana Macek Jilkova, Caroline Aspord, Keerthi Kurma, Anouck Granon, Christian Sengel, Nathalie Sturm, Patrice N Marche, Thomas Decaens

Abstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Intratumoral PD-1Cellular oncology (Dordrecht, Netherlands) · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zuzana Macek JilkovaInstitute for Advanced Biosciences, Université Grenoble-Alpes, Saint-Martin-d'Hères, France.
Caroline AspordInstitute for Advanced Biosciences, Université Grenoble-Alpes, Saint-Martin-d'Hères, France.
Keerthi KurmaInstitute for Advanced Biosciences, Université Grenoble-Alpes, Saint-Martin-d'Hères, France.
Anouck GranonInstitute for Advanced Biosciences, Université Grenoble-Alpes, Saint-Martin-d'Hères, France.
Christian SengelService de radiologie, CHU Grenoble Alpes, France.
Nathalie SturmInstitute for Advanced Biosciences, Université Grenoble-Alpes, Saint-Martin-d'Hères, France.
Patrice N MarcheInstitute for Advanced Biosciences, Université Grenoble-Alpes, Saint-Martin-d'Hères, France.
Thomas DecaensInstitute for Advanced Biosciences, Université Grenoble-Alpes, Saint-Martin-d'Hères, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Today, a promising treatment strategy is focused on the enhancement of antitumor immune responses by immune checkpoint modification. However, as only 20% of patients with HCC are responders, identification of predictive factors is urgently required. Therefore, for the first time, the features of the intrahepatic and circulating immune system in patients with advanced-stage HCC, before and during the treatment, were analyzed.

methodsWe collected fresh HCC biopsies, along with adjacent tumor-free liver tissues and peripheral blood samples, from 21 patients with advanced HCC. Furthermore, we performed an extensive immunomonitoring of patients with HCC treated with sorafenib or programmed death (PD)-1/PD-L1 pathway blockade using multiparametric flow cytometry.

resultsWe observed that regardless of the treatment, low baseline intratumoral CD4/CD8 T-cell ratio was associated with better overall survival (P = 0.0002). The baseline frequency of intratumoral PD-1 CD8 T cells was significantly lower in patients responding to sorafenib treatment than in the nonresponders (P = 0.0117), and the frequency of circulating PD-1 T cells increased with tumor progression (P = 0.0329). By contrast, responders to PD-1/PD-L1 pathway blockade showed a trend of high baseline frequency of intratumoral PD-1 CD8 T cells. Moreover, we observed a trend of LAG3 and TIM3 upregulation on circulating T cells in nonresponding patients to PD-1/PD-L1 pathway blockade. DISCUSSION: Immunosuppressive state, characterized by an enhanced intratumoral CD4/CD8 T-cell ratio, was associated with poor prognosis. Additionally, our results suggest that the frequency of intratumoral PD-1 CD8 T cells may serve as a biomarker to identify which individuals will benefit from which treatment and support the use of combination strategies.

Indexed as

AgedAntigens, CDCarcinoma, HepatocellularCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDisease ProgressionFemaleHepatitis A Virus Cellular Receptor 2HumansImmunotherapyLiver NeoplasmsLymphocyte Activation Gene 3 ProteinMaleNeoplasm StagingPredictive Value of TestsPrognosisAntigens, CDHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Lag3 protein, humanLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsSorafenib

Identifiers

PMID31295151
PMCPMC6708670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.